Circulating microRNA as Biomarkers in Hematological Malignancies
- 26 November 2015
- book chapter
- other
- Published by Springer Science and Business Media LLC
- Vol. 106, 123-138
- https://doi.org/10.1007/978-3-0348-0955-9_5
Abstract
Hematopoiesis is a highly regulated process controlled by a complex network of molecular mechanisms that simultaneously regulate differentiation, proliferation, and apoptosis of hematopoietic stem cells. Aberrant microRNA (miRNA) expression could affect normal hematopoiesis, leading to the development of hematological malignancies. Hematologic cancers, which are caused by malignant transformation of cells of the bone marrow and the lymphatic system, are usually divided into three major groups: leukemias, lymphomas, and monoclonal gammopathies. Hematologic malignancies are highly aggressive diseases with high morbidity and mortality. For these reasons, early and easily obtainable markers for diagnosis, risk stratification, and follow-up are essential for improvement of outcome and survival of these patients. Recent studies have provided new insights about the diagnostic value of expression patterns of miRNAs in serum/plasma in these diseases. While the use of circulating miRNAs is only at the experimental level, it appears to have a great potential. This chapter deals with the use of circulating miRNAs as minimally invasive biomarkers in hematologic malignancies.Keywords
This publication has 52 references indexed in Scilit:
- PROGNOSTIC FACTORS IN HODGKIN LYMPHOMAMediterranean Journal of Hematology and Infectious Diseases, 2014
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemiaBlood, 2013
- Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemiaJournal of Translational Medicine, 2013
- Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphomaAnnals of Hematology, 2011
- Diagnostic microRNAs in myelodysplastic syndromeExperimental Hematology, 2011
- MiR-15a and miR-16-1 cluster functions in human leukemiaProceedings of the National Academy of Sciences of the United States of America, 2008
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulationProceedings of the National Academy of Sciences of the United States of America, 2005
- Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachBlood, 2005
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2002